Literature DB >> 19807549

Costs of multiple myeloma and associated skeletal-related events in The Netherlands.

Martijn T Groot1, Peter C Huijgens, Pierre J Wijermans, Carin A Uyl-de Groot.   

Abstract

Multiple myeloma causes significant skeletal morbidity (e.g., pain and pathologic fractures) resulting from osteolytic lesions, and the associated medical costs can be considerable. Therefore, the authors of this review conducted a retrospective cost analysis to quantify the medical costs associated with skeletal complications in patients treated for multiple myeloma in The Netherlands. In total, 20 patient records were investigated, and costs are given in euros. This analysis demonstrated that skeletal complications related to multiple myeloma contribute significantly to the cost of care, comprising approximately 17% of the total cost of treatment. This study provides a model for further investigation of the health-economic impact of skeletal complications in patients with malignant bone disease.

Entities:  

Year:  2004        PMID: 19807549     DOI: 10.1586/14737167.4.5.565

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  2 in total

1.  Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.

Authors:  Ramón García-Sanz; Albert Oriol; María J Moreno; Javier de la Rubia; Angel R Payer; Miguel T Hernández; Luis Palomera; Ana I Teruel; María J Blanchard; Mercedes Gironella; Paz Ribas; Joan Bargay; Eugenia Abellá; Miquel Granell; Enrique M Ocio; Josep M Ribera; Jesús F San Miguel; María V Mateos
Journal:  Haematologica       Date:  2015-06-11       Impact factor: 9.941

Review 2.  Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.

Authors:  Kate McKeage; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.